Are we just a year away from ‘antibiotic’ style cancer cure?
Israeli scientists believe they have found an anti-biotic style cure for cancer.
Dan Aridor, says of a new treatment being developed by his company, Accelerated Evolution Biotechnologies: “We believe we will offer in a year’s time a complete cure for cancer.”
His company was founded at the turn of the century at the ITEK incubator in the Weizmann Science Park, in Rehovot, Israel.
In his astonishing statement he said: “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.
“Our solution will be both generic and personal.”
However, there are sceptics and Dr Ben Neel, director of Perlmutter Cancer Center at NYU Langone Health, is reported as saying: “Of course, curing cancer is the goal of everyone who comes to work every day at a cancer center — and if this company does, in fact, cure cancer, they will have my congratulations and thanks.
“But cancer is multiple diseases, and it is highly unlikely that this company has found a ‘cure’ for cancer, any more than there is a single cure for infections.”
Andor’s claim comes at a time when more than 18 million new cancer cases are diagnosed each year across the world, according to the International Agency for Research on Cancer.
And shocking statistics show that one-in-six deaths across the world are due to cancer, making it the second biggest killer, hard on the heels of cause of cardiovascular disease.
Aridor, chairman Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) is essentially a cancer antibiotic.
It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria.
“The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used,” Dr Morad said.
“Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”
However, reports say it has not been tested in humans yet, although Aridor claims it has been successful in mice and is almost ready for the clinical trials.